ChiCTR1900021263
尚未开始
/
/
/
2019-02-04
/
/
CBD stones
Surgical (Open and laparoscopic) management of large difficult CBD ston
Surgical (Open and laparoscopic) management of large difficult CBD stones after different sessions of endoscopic failure
To the best of our knowledge, there is little literature on surgical management of difficult CBD stones after ERCP failure, so, our study aimed to analyze this issue.
队列研究
Ⅰ期
No randomozation( retrospective study)
N/A
none( authors funding)
/
85
/
2013-01-20
2018-06-20
/
1. patients underwent surgical management of large difficult CBDS after ERCP failure; 2. in the period from the beginning of 2013 to the beginning of 2018; 3. in the department of hepato-pancreato-biliary (HPB) surgery (tertiary care center), National Liver Institute (NLI), University of Menoufia, Menoufia, Egypt.；
请登录查看1-cases with data loss, 2-those who did not complete the follow-up 3-who refused researches；
请登录查看埃及梅努菲亚大学国家肝病研究所
/
埃及梅努菲亚大学国家肝病研究所的其他临床试验
- Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma
- Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study
- Surgical (Open and laparoscopic) management of large difficult CBD ston
埃及梅努菲亚大学国家肝病研究所的其他临床试验
- Short- and long-term outcomes after Kasai operation for type III biliary atresia: Twenty years of experience in a single tertiary Egyptian centre.
- Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma
- The Impact of Clinicopathological factors on long-term patient survival Post Whipple's operation for periampullary carcinoma
- Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study
- Surgical (Open and laparoscopic) management of large difficult CBD ston
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04